Application of 21-gene recurrence score in patients with T1-2, N0-1 ER-positive/HER2 negative breast cancer: Survival analysis in relation to clinical risk score

被引：0
|
作者：
Bae, Soong June [1 ]
Ahn, Sung Gwe [1 ]
Park, Soeun [1 ]
Cha, Chi Hwan [1 ]
Kim, Dooreh [1 ]
Lee, Janghee [1 ]
Jeong, Joon [1 ]
机构：
[1] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Seoul, South Korea
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
breast neoplasm; adjuvant treatment; 21-gene recurrence score; chemotherapy;
D O I：
10.1158/1538-7445.SABCS19-P3-08-68
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-08-68
引用
收藏
页数：2
相关论文
共 50 条
  • [1] 21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
    Zhang, Wen-Wen
    Tong, Qin
    Sun, Jia-Yuan
    Hua, Xin
    Long, Zhi-Qing
    Deng, Jia-Peng
    Dong, Yong
    Li, Fang-Yan
    He, Zhen-Yu
    Wu, San-Gang
    Lin, Huan-Xin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [2] Comparisons of tumor-infiltrating lymphocytes and 21-gene recurrence score in ER-positive/ HER2-negative breast cancer
    Ahn, S. G.
    Cha, Y. J.
    Yoon, C.
    Bae, S. J.
    Kim, J.
    Jeong, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
    Ahn, Sung Gwe
    Cha, Yoon Jin
    Bae, Soon June
    Yoon, Chanik
    Lee, Hak Woo
    Jeong, Joon
    BMC CANCER, 2018, 18
  • [4] Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
    Sung Gwe Ahn
    Yoon Jin Cha
    Soon June Bae
    Chanik Yoon
    Hak Woo Lee
    Joon Jeong
    BMC Cancer, 18
  • [5] HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+Breast Cancer With Early Recurrence
    Yamashita, Hiroko
    Ishida, Naoko
    Hatanaka, Yutaka
    Hagio, Kanako
    Oshino, Tomohiro
    Takeshita, Takashi
    Kanno-Okada, Hiromi
    Shimizu, Ai
    Hatanaka, Kanako C.
    Matsuno, Yoshihiro
    ANTICANCER RESEARCH, 2020, 40 (02) : 645 - 652
  • [6] First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Giarratano, Tommaso
    Mion, Marta
    Tortora, Giampaolo
    De Rossi, Costanza
    Gori, Stefania
    Oliani, Cristina
    Merlini, Laura
    Pasini, Felice
    Bonciarelli, Giorgio
    Griguolo, Gaia
    Orvieto, Enrico
    Michieletto, Silvia
    Saibene, Tania
    Del Bianco, Paola
    De Salvo, Gian Luca
    Conte, PierFranco
    ONCOLOGIST, 2018, 23 (03): : 297 - 305
  • [7] Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
    Bae, Soong June
    Ahn, Sung Gwe
    Ji, Jung Hwan
    Chu, Chihhao
    Kim, Dooreh
    Lee, Janghee
    Cha, Yoon Jin
    Jeong, Joon
    CANCERS, 2021, 13 (16)
  • [8] 21-gene recurrence score® in patients with primary metastatic ER+HER2-breast cancer
    Barinoff, J.
    Anastasiadou, L.
    Brandi, C.
    Junker-Stein, A.
    Silbermann, J.
    Langenfeld, M.
    Fortmann, C.
    Thill, M.
    CANCER RESEARCH, 2017, 77
  • [9] Do all patients with early breast cancer (T1 T2 N0-1) with ER, PR positive and Her 2 neu negative require adjuvant chemotherapy? - Role of risk score
    Kumar, R.
    Daga, G.
    BREAST, 2019, 44 : S98 - S98
  • [10] 21-Gene Recurrence Score Assay Predicts Benefit of Post-Mastectomy Radiotherapy in T1-2 N1 Breast Cancer
    Goodman, Chelain R.
    Seagle, Brandon-Luke L.
    Kocherginsky, Masha
    Donnelly, Eric D.
    Shahabi, Shohreh
    Strauss, Jonathan B.
    CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3878 - 3887
12345